Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A

Phase 3

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: Turoctocog alfa pegol

First Posted Date: 2018-05-18

Last Posted Date: 2022-12-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 160

Registration Number: NCT03528551

Locations: 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom

In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database

Completed

Conditions: Obesity
Overweight

Interventions: Drug: Liraglutide

First Posted Date: 2018-03-27

Last Posted Date: 2022-11-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 105

Registration Number: NCT03479762

Locations: 🇩🇰
Novo Nordisk Investigational Site, Soeborg, Denmark

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

Phase 1

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: NNC0194-0499
Drug: Placebo

First Posted Date: 2018-03-27

Last Posted Date: 2019-06-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 57

Registration Number: NCT03479892

Locations: 🇺🇸
Novo Nordisk Investigational Site, San Antonio, Texas, United States

A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide
Drug: Probenecid
Drug: Ciclosporin

First Posted Date: 2018-03-15

Last Posted Date: 2019-06-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 21

Registration Number: NCT03466567

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide

First Posted Date: 2018-03-07

Last Posted Date: 2021-09-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 462

Registration Number: NCT03457012

Locations: 🇨🇦
Novo Nordisk Investigational Site, Cambridge, Ontario, Canada

Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1 Diabetes

Interventions: Drug: Fast-acting insulin aspart

First Posted Date: 2018-03-01

Last Posted Date: 2020-03-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 320

Registration Number: NCT03450863

Locations: 🇩🇪
Novo Nordisk Investigational Site, Schweinfurt, Germany

Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period

Phase 4

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: turoctocog alfa

First Posted Date: 2018-02-28

Last Posted Date: 2020-04-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 60

Registration Number: NCT03449342

Locations: 🇮🇳
Novo Nordisk Investigational Site, New Delhi, India

First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: NNC9204-1513
Drug: Glucagon
Drug: Placebo

First Posted Date: 2018-02-23

Last Posted Date: 2018-09-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT03444467

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)

Completed

Conditions: Genetic Disorder
Noonan Syndrome

Interventions: Drug: Somatropin

First Posted Date: 2018-02-19

Last Posted Date: 2022-11-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 71

Registration Number: NCT03435627

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

Awareness, Care, and Treatment In Obesity Management of Patients With Hemophilia (ACTION) to Inform Hemophilia Obesity Patient Empowerment (HOPE)

Completed

Conditions: Haemophilia A, Haemophilia B, Obesity

Interventions: Other: No treatment given

First Posted Date: 2018-02-12

Last Posted Date: 2018-09-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 317

Registration Number: NCT03430154

Locations: 🇺🇸
Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy